<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01796912</url>
  </required_header>
  <id_info>
    <org_study_id>1880</org_study_id>
    <nct_id>NCT01796912</nct_id>
  </id_info>
  <brief_title>Lipoprotein Apheresis in Refractory Angina Study</brief_title>
  <official_title>Clinical Outcomes, Perfusion and Vascular Function in Patients With Refractory Angina and Raised Lipoprotein (a), Treated With Lipoprotein Apheresis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to determine the impact of apheresis on clinical parameters and
      symptoms of patients with refractory angina and raised Lp(a). The investigators will conduct
      a prospective, randomised controlled crossover study of 20 patients with refractory angina
      and raised Lp(a), randomised to undergoing lipoprotein apheresis weekly for three months or
      sham apheresis weekly for three months with assessment of myocardial perfusion, carotid
      atherosclerosis, endothelial vascular function, thrombogenesis, exercise capacity, angina
      symptoms and quality of life at the beginning and end of treatment. Patients will then
      crossover to the opposite study arm with the protocol repeated. The hypothesis is that the
      above parameters will be improved by lipoprotein apheresis in patients with raised Lp(a) and
      Refractory Angina. Investigators will also test for the genotypic presence of
      apolipoprotein(a) gene (LPA) locus variants (rs10455872 and rs3798220) which are thought to
      be associated with an increased level of Lp(a) and an increased risk of coronary disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Angina which is refractory to conventional medical therapy and revascularisation is
      challenging to manage. Lipoprotein(a) or Lp(a) is a genetically determined form of
      LDL-cholesterol, elevation of which is an independent risk factor and predictor of adverse
      cardiovascular events. Lp(a) is felt to increase cardiovascular risk via its prothrombotic
      effect and by enhancing intimal lipoprotein deposition. Lipoprotein apheresis is the most
      effective treatment for raised Lp(a). Lipid lowering agents such as statins have little to no
      effect on Lp(a) levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2013</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Quantitative Myocardial Perfusion Measured by Stress/Rest Cardiovascular Magnetic Resonance Imaging</measure>
    <time_frame>3 months</time_frame>
    <description>Baseline compare to 3 month, changes presented Determine the impact of lipoprotein apheresis on quantitative myocardial perfusion measured by stress/rest cardiovascular magnetic resonance imaging.
Increase means better outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Carotid Atherosclerosis/Plaque Burden Determined by Cardiovascular Magnetic Resonance Imaging</measure>
    <time_frame>3 months</time_frame>
    <description>Changes from baseline to 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Endothelial Vascular Function</measure>
    <time_frame>Within 7 days before and after 3 months of weekly lipoprotein apheresis</time_frame>
    <description>EndoPat LnRHI - natural logarithm of reactive hyperaemia index. Increase - better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Seattle Angina Questionnaire Score</measure>
    <time_frame>3 months</time_frame>
    <description>SAQâ€”Angina stability, increase means improvement. 0-100 scale, Higher score means improvements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SF-36 Quality of Life Score</measure>
    <time_frame>3 months</time_frame>
    <description>Quality of Life score following, 0-100 score, high score improve quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Exercise Capacity Determined by Six Minute Walk Test</measure>
    <time_frame>3 months</time_frame>
    <description>Six minute walk test, patient can walk longer distance means improvements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Markers of Thrombogenesis</measure>
    <time_frame>3 months</time_frame>
    <description>Thrombogenesis, Reduce value is better to the patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Refractory Angina</condition>
  <condition>Raised Lipoprotein(a)&gt;50mg/dL or &gt;500mg/L</condition>
  <arm_group>
    <arm_group_label>First Lipoprotein Apheresis, then sham apheresis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three months of weekly lipoprotein apheresis, 1 month washout, then three month sham apheresis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First Sham Apheresis, then Lipoprotein Apheresis</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Three months of weekly sham apheresis, 1 month washout, then three month lipoprotein Apheresis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lipoprotein Apheresis</intervention_name>
    <description>Weekly lipoprotein apheresis for 3 months</description>
    <arm_group_label>First Lipoprotein Apheresis, then sham apheresis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Apheresis</intervention_name>
    <description>Weekly sham (placebo) apheresis for 3 months</description>
    <arm_group_label>First Sham Apheresis, then Lipoprotein Apheresis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with refractory angina for more than three months.

          -  Two or more episodes of angina per week.

          -  Previous history of myocardial infarction, coronary artery bypass graft (CABG)
             surgery,percutaneous coronary intervention (PCI) or any combination of the above.

          -  Prescribed optimal medical therapy.

          -  Hypercholesterolaemia with an elevated Lp(a) &gt; 50mg/dL and an LDL-cholesterol less
             than 4.0mmol/L despite optimal lipid lowering drug therapy.

        Exclusion Criteria:

          -  Patients with poor calibre veins for cannulation.

          -  Patients with any other chronic systemic illness such as liver or renal failure,
             neoplastic disease, overt cardiac failure, unstable coronary artery disease, coronary
             revascularisation or a myocardial infarction within the previous eight weeks.

          -  Pregnancy, untreated diabetes mellitus, untreated arterial hypertension, and those
             with general contraindications to undergoing Cardiovascular magnetic resonance imaging
             or contraindications to adenosine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dudley Pennell, MB BChir MA MD FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahmoud Barbir, MB BCh, FRCP</last_name>
    <role>Study Director</role>
    <affiliation>Royal Brompton and Harfield Hospital, Imperial College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Brompton and Harefield NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Khan TZ, Hsu LY, Arai AE, Rhodes S, Pottle A, Wage R, Banya W, Gatehouse PD, Giri S, Collins P, Pennell DJ, Barbir M. Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial. Eur Heart J. 2017 May 21;38(20):1561-1569. doi: 10.1093/eurheartj/ehx178.</citation>
    <PMID>28453721</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 15, 2013</study_first_submitted>
  <study_first_submitted_qc>February 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2013</study_first_posted>
  <results_first_submitted>August 9, 2019</results_first_submitted>
  <results_first_submitted_qc>October 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 12, 2019</results_first_posted>
  <last_update_submitted>October 21, 2019</last_update_submitted>
  <last_update_submitted_qc>October 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Refractory Angina</keyword>
  <keyword>Lipoprotein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>First Lipoprotein Apheresis, Then Sham Apheresis</title>
          <description>Three months of weekly lipoprotein apheresis, 1 month of washout then three month of sham apheresis</description>
        </group>
        <group group_id="P2">
          <title>First Sham Apheresis, Then Lipoprotein Apheresis</title>
          <description>Three months of weekly sham apheresis, 1 month of washout then three months of weekly lipoprotein apheresis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participant</title>
          <description>Participant were randomised to undergoing lipoprotein apheresis weekly for three months or sham apheresis weekly for three months with assessment of myocardial perfusion, carotid atherosclerosis, endothelial vascular function, thrombogenesis, exercise capacity, angina symptoms and quality of life at the beginning and end of treatment. Patients then crossovered to the opposite study arm with the protocol repeated.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.9" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Quantitative Myocardial Perfusion Measured by Stress/Rest Cardiovascular Magnetic Resonance Imaging</title>
        <description>Baseline compare to 3 month, changes presented Determine the impact of lipoprotein apheresis on quantitative myocardial perfusion measured by stress/rest cardiovascular magnetic resonance imaging.
Increase means better outcome</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lipoprotein Apheresis</title>
            <description>Three months of weekly lipoprotein apheresis</description>
          </group>
          <group group_id="O2">
            <title>Sham Apheresis</title>
            <description>Three months of weekly sham apheresis</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Quantitative Myocardial Perfusion Measured by Stress/Rest Cardiovascular Magnetic Resonance Imaging</title>
          <description>Baseline compare to 3 month, changes presented Determine the impact of lipoprotein apheresis on quantitative myocardial perfusion measured by stress/rest cardiovascular magnetic resonance imaging.
Increase means better outcome</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" lower_limit="0.31" upper_limit="0.63"/>
                    <measurement group_id="O2" value="-0.16" lower_limit="-0.33" upper_limit="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Carotid Atherosclerosis/Plaque Burden Determined by Cardiovascular Magnetic Resonance Imaging</title>
        <description>Changes from baseline to 3 months</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lipoprotein Apheresis</title>
            <description>Lipoprotein Apheresis: Weekly lipoprotein apheresis for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Sham Apheresis</title>
            <description>Sham Apheresis: Weekly sham (placebo) apheresis for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Carotid Atherosclerosis/Plaque Burden Determined by Cardiovascular Magnetic Resonance Imaging</title>
          <description>Changes from baseline to 3 months</description>
          <units>mm3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-335" lower_limit="-423" upper_limit="-247"/>
                    <measurement group_id="O2" value="127" lower_limit="72" upper_limit="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Endothelial Vascular Function</title>
        <description>EndoPat LnRHI - natural logarithm of reactive hyperaemia index. Increase - better outcome</description>
        <time_frame>Within 7 days before and after 3 months of weekly lipoprotein apheresis</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lipoprotein Apheresis</title>
            <description>Three months of weekly lipoprotein apheresis</description>
          </group>
          <group group_id="O2">
            <title>Sham Apheresis</title>
            <description>Three months of weekly sham apheresis</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Endothelial Vascular Function</title>
          <description>EndoPat LnRHI - natural logarithm of reactive hyperaemia index. Increase - better outcome</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" lower_limit="-0.08" upper_limit="0.19"/>
                    <measurement group_id="O2" value="-0.03" lower_limit="-0.18" upper_limit="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Seattle Angina Questionnaire Score</title>
        <description>SAQâ€”Angina stability, increase means improvement. 0-100 scale, Higher score means improvements</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lipoprotein Apheresis</title>
            <description>Three months of weekly lipoprotein apheresis</description>
          </group>
          <group group_id="O2">
            <title>Sham Apheresis</title>
            <description>Three months of weekly sham apheresis</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Seattle Angina Questionnaire Score</title>
          <description>SAQâ€”Angina stability, increase means improvement. 0-100 scale, Higher score means improvements</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="6.7" upper_limit="28.3"/>
                    <measurement group_id="O2" value="-1.75" lower_limit="-17.1" upper_limit="9.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SF-36 Quality of Life Score</title>
        <description>Quality of Life score following, 0-100 score, high score improve quality of life</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lipoprotein Apheresis</title>
            <description>Three months of weekly lipoprotein apheresis</description>
          </group>
          <group group_id="O2">
            <title>Sham Apheresis</title>
            <description>Three months of weekly sham apheresis</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SF-36 Quality of Life Score</title>
          <description>Quality of Life score following, 0-100 score, high score improve quality of life</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="5" upper_limit="13"/>
                    <measurement group_id="O2" value="-2" lower_limit="-4.5" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Exercise Capacity Determined by Six Minute Walk Test</title>
        <description>Six minute walk test, patient can walk longer distance means improvements</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lipoprotein Apheresis</title>
            <description>Three months of weekly lipoprotein apheresis</description>
          </group>
          <group group_id="O2">
            <title>Sham Apheresis</title>
            <description>Three months of weekly sham apheresis</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Exercise Capacity Determined by Six Minute Walk Test</title>
          <description>Six minute walk test, patient can walk longer distance means improvements</description>
          <units>meter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" lower_limit="41.5" upper_limit="105.5"/>
                    <measurement group_id="O2" value="3.5" lower_limit="-15.1" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Markers of Thrombogenesis</title>
        <description>Thrombogenesis, Reduce value is better to the patients</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lipoprotein Apheresis</title>
            <description>Three months of weekly lipoprotein apheresis</description>
          </group>
          <group group_id="O2">
            <title>Sham Apheresis</title>
            <description>Three months of weekly sham apheresis</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Markers of Thrombogenesis</title>
          <description>Thrombogenesis, Reduce value is better to the patients</description>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-355" lower_limit="-738" upper_limit="-88.5"/>
                    <measurement group_id="O2" value="36" lower_limit="-56" upper_limit="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lipoprotein Apheresis</title>
          <description>Three months of weekly lipoprotein apheresis</description>
        </group>
        <group group_id="E2">
          <title>Sham Apheresis</title>
          <description>Three months of weekly sham apheresis</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dudley Pennell</name_or_title>
      <organization>Imperiwal College London</organization>
      <phone>+44 (0)20 3811 6871</phone>
      <email>d.pennell@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

